Hitachi and MD Anderson to collaborate in research in oropharyngeal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hitachi Healthcare Americas Corp. and MD Anderson Cancer Center announced an agreement to collaborate on a randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy versus intensity-modulated photon therapy for the treatment of oropharyngeal cancer of the head and neck.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login